Clínica Universidad de Navarra, C. del Marquesado de Santa Marta 1, 28027 Madrid, Spain.
Clínica Universidad de Navarra, C. del Marquesado de Santa Marta 1, 28027 Madrid, Spain.
Endocrinol Diabetes Nutr (Engl Ed). 2024 Dec;71(10):447-453. doi: 10.1016/j.endien.2024.11.012.
GLP1 receptor agonists (GLP1-RAs) are currently the most widely used pharmacological option to treat obesity. However, considerable heterogeneity in weight loss response has been observed with different anti-obesity drugs and response predictors to these drugs still remain ambiguous. Furthermore, very few published data have been available on cases of high-responders to treatment with GLP1-RAs. In this article, we present the case of a patient with grade 4 obesity (initial body mass index, 50.2kg/m) with associated mechanical and metabolic complications who achieved an initial weight loss of 40% at 1 year with hygienic-dietary measures and drug treatment with liraglutide. We also review the available literature on factors potentially contributing to variations in weight loss with GLP1-RAs in general and liraglutide, in particular.
GLP1 受体激动剂 (GLP1-RAs) 是目前治疗肥胖症最广泛使用的药物选择。然而，不同的抗肥胖药物在体重减轻反应方面存在相当大的异质性，这些药物的反应预测因素仍然不清楚。此外，关于 GLP1-RAs 治疗的高反应者的病例，很少有发表的数据。在本文中，我们介绍了一例患有 4 级肥胖症（初始体重指数为 50.2kg/m）的患者，伴有机械和代谢并发症，通过卫生饮食措施和利拉鲁肽药物治疗，在 1 年内体重减轻了 40%。我们还回顾了关于 GLP1-RAs 一般和利拉鲁肽特别导致体重减轻变化的潜在因素的现有文献。
